As their results imply, integrating proteomic and imaging data improved early detection of NAFLD and suggested that PON1 may serve as both a biomarker and therapeutic target in obesity-associated liver disease. This evidence concerns the gene PON1 and obesity due to melanocortin 4 receptor deficiency.